|
1
|
Sanders JE, Im HJ, Hoffmeister PA, Gooley
TA, Woolfrey AE, Carpenter PA, Andrews RG, Bryant EM and Appelbaum
FR: Allogeneic hematopoietic cell transplantation for infants with
acute lymphoblastic leukemia. Blood. 105:3749–3756. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pieters R and Carroll WL: Biology and
treatment of acute lymphoblastic leukemia. Pediatr Clin North Am.
55:1–20, ix. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Izbicki G, Rudensky B, Na'amad M, Hershko
C, Huerta M and Hersch M: Transfusion-related leukocytosis in
critically ill patients. Crit Care Med. 32:439–442. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Deng CH and Zhang QP: Leukemia stem cells
in drug resistance and metastasis. Chin Med J (Eng1). 123:954–960.
2010.
|
|
5
|
Bhojwani D and Pui CH: Relapsed childhood
acute lymphoblastic leukaemia. Lancet Oncol. 14:e205–e217. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pui C-H, Gaynon PS, Boyett JM, Chessells
JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DO, Vilmer
E, et al: Outcome of treatment in childhood acute lymphoblastic
leukaemia with rearrangements of the 11q23 chromosomal region.
Lancet. 359:1909–1915. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tzounakas VL, Seghatchian J, Grouzi E,
Kokoris S and Antonelou MH: Red blood cell transfusion in surgical
cancer patients: Targets, risks, mechanistic understanding and
further therapeutic opportunities. Transfus Apheresis Sci.
56:291–304. 2017. View Article : Google Scholar
|
|
8
|
Cata JP, Wang H, Gottumukkala V, Reuben J
and Sessler DI: Inflammatory response, immunosuppression, and
cancer recurrence after perioperative blood transfusions. Br J
Anaesth. 110:690–701. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koehl U, Sörensen J, Esser R, Zimmermann
S, Grüttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T and
Schwabe D: IL-2 activated NK cell immunotherapy of three children
after haploidentical stem cell transplantation. Blood Cells Mol
Dis. 33:261–266. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tvedt TH, Lie SA, Reikvam H, Rye KP,
Lindås R, Gedde-Dahl T, Ahmed AB and Bruserud Ø: Pretransplant
levels of CRP and interleukin-6 family cytokines; effects on
outcome after allogeneic stem cell transplantation. Int J Mol Sci.
17:E18232016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jordan SC, Choi J, Kim I, Wu G, Toyoda M,
Shin B and Vo A: Interleukin-6, a cytokine critical to mediation of
inflammation, autoimmunity and allograft rejection: Therapeutic
implications of IL-6 receptor blockade. Transplantation. 101:32–44.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Murakami S: Soluble interleukin-2 receptor
in cancer. Front Biosci. 9:3085–3090. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Katsuya H, Yamanaka T, Ishitsuka K,
Utsunomiya A, Sasaki H, Hanada S, Eto T, Moriuchi Y, Saburi Y,
Miyahara M, et al: Prognostic index for acute- and lymphoma-type
adult T-cell leukemia/lymphoma. J Clin Oncol. 30:1635–1640. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goto H, Tsurumi H, Takemura M,
Ino-Shimomura Y, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K,
Goto N, et al: Serum-soluble interleukin-2 receptor (sIL-2R) level
determines clinical outcome in patients with aggressive
non-Hodgkin's lymphoma: In combination with the International
Prognostic Index. J Cancer Res Clin Oncol. 131:73–79. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goto N, Tsurumi H, Goto H, Shimomura YI,
Kasahara S, Hara T, Yasuda I, Shimizu M, Murakami N, Yoshikawa T,
et al: Serum soluble interleukin-2 receptor (sIL-2R) level is
associated with the outcome of patients with diffuse large B cell
lymphoma treated with R-CHOP regimens. Ann Hematol. 91:705–714.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bhojwani D, Yang JJ and Pui CH: Biology of
childhood acute lymphoblastic leukemia. Pediatr Clin North Am.
62:47–60. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pape A, Stein P, Horn O and Habler O:
Clinical evidence of blood transfusion effectiveness. Blood
Transfus. 7:250–258. 2009.PubMed/NCBI
|
|
18
|
Smolen JS and Maini RN: Interleukin-6: A
new therapeutic target. Arthritis Res Ther. 8(Suppl 2): S52006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Soker M, Colpan L, Ece A, Devecioğlu C and
Haspolat K: Serum levels of IL-1 beta, sIL-2R, IL-6, IL-8, and
TNF-alpha in febrile children with cancer and neutropenia. Med
Oncol. 18:51–57. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stachura A, Król R, Poplawski T, Michalik
D, Pomianowski S, Jacobsson M, Aberg M and Bengtsson A: Transfusion
of intra-operative autologous whole blood: Influence on complement
activation and interleukin formation. Vox Sang. 100:239–246. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshida N, Oda M, Kuroda Y, Katayama Y,
Okikawa Y, Masunari T, Fujiwara M, Nishisaka T, Sasaki N, Sadahira
Y, et al: Clinical significance of sIL-2R levels in B-cell
lymphomas. PLoS One. 8:e787302013. View Article : Google Scholar : PubMed/NCBI
|
